The Federation of American Societies for Experimental Biology called for a re-examination of the way research is funded in the U.S., in a report detailing the challenges facing researchers and the threats to continued progress in the field.
NAIYER RIZVI was named director of thoracic oncology and immunotherapeutics in medical oncology at NewYork-Presbyterian/Columbia University Medical Center. Rizvi comes from Memorial Sloan Kettering Cancer Center, where he was an attending physician and focused on thoracic immunotherapy.
JULIE BRAHMER was named director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.
AVEO Oncology announced plans to cut its workforce by two-thirds, end its internal research functions, and vacate up to 80 percent of its facilities, including laboratory and vivarium locations. The biotechnology company was co-founded by Ronald DePinho, president of MD Anderson Cancer Center.
The stochastic process of stem cell divisions should not be equated with bad luck, said Barnett Kramer, director of the NCI Division of Cancer Prevention, focusing on misinterpretations of the “Bad Luck” paper by Cristian Tomasetti and Bert Vogelstein, of Johns Hopkins University School of Medicine.
How much of the potential to develop cancer is due to plain “bad luck”?
In May 2008, the Blue Devils of genomic medicine were facing a mortal threat.
MD Anderson, Intrexon, and Ziopharm announce sublicensing agreement with the University of Minnesota
MD ANDERSON CANCER CENTER, Intrexon Corporation and Ziopharm Oncology announced a sublicensing agreement for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
AMGEN and MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen's bispecific T cell engager antibody constructs, an immunotherapy that serves as a bridge between T cells and cancer cells.
A. EUGENE WASHINGTON was named chancellor for health affairs at Duke University, as well as president and chief executive officer of the Duke University Health System, effective April 1.
